Company intelligence / Profile preview

Foli Bio

New York, NY, United Statesfoli.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Foli Bio has developed a next-generation non-invasive RNA sequencing platform ("Exfo-seq") that enables robust quantification of host gene expression directly from stool samples. The technology is being positioned for precision medicine applications, particularly in gastrointestinal diseases. The company is scaling operations with pharma partners and academic collaborations, moving from preclinical validation toward clinical studies.

Therapeutic areas: Gastroenterology
Modalities: RNA-based diagnosticsPlatform technology (Exfo-seq)
Industry: Molecular Diagnostics

Partnerships

Top five global pharmaceutical company (undisclosed; referenced as a major pharma partner for preclinical-to-clinical projects)

Beyond the preview

Go deeper on Foli Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foli Bio.

Explore the full profile